1. Home
  2. CODA vs BNR Comparison

CODA vs BNR Comparison

Compare CODA & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coda Octopus Group Inc.

CODA

Coda Octopus Group Inc.

HOLD

Current Price

$10.08

Market Cap

113.3M

Sector

Industrials

ML Signal

HOLD

Logo Burning Rock Biotech Limited

BNR

Burning Rock Biotech Limited

HOLD

Current Price

$9.79

Market Cap

99.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CODA
BNR
Founded
1994
2014
Country
United States
China
Employees
N/A
667
Industry
Industrial Machinery/Components
Medical Specialities
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.3M
99.7M
IPO Year
2007
2019

Fundamental Metrics

Financial Performance
Metric
CODA
BNR
Price
$10.08
$9.79
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
58.3K
5.8K
Earning Date
06-15-2026
06-05-2026
Dividend Yield
N/A
N/A
EPS Growth
15.62
N/A
EPS
0.23
N/A
Revenue
$20,316,161.00
N/A
Revenue This Year
$18.28
$111.65
Revenue Next Year
$12.62
N/A
P/E Ratio
$43.70
N/A
Revenue Growth
4.98
N/A
52 Week Low
$7.80
$6.79
52 Week High
$18.00
$41.72

Technical Indicators

Market Signals
Indicator
CODA
BNR
Relative Strength Index (RSI) 49.52 46.25
Support Level $9.85 $8.83
Resistance Level $10.50 $10.72
Average True Range (ATR) 0.32 0.76
MACD -0.01 -0.00
Stochastic Oscillator 33.02 18.86

Price Performance

Historical Comparison
CODA
BNR

About CODA Coda Octopus Group Inc.

Coda Octopus Group Inc develops underwater technologies and equipment for imaging, mapping defense, and survey applications. The company operates in three distinct business segments: the Marine Technology business, Acoustic Sensors and Material Business and the Defense Engineering Services Business. Its geographical segments are the Americas, Europe, Australia/Asia, and the Middle East/Africa. The majority of revenue is derived from the Products segment.

About BNR Burning Rock Biotech Limited

Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.

Share on Social Networks: